{"title":"以肠促胰岛素为基础的治疗在2型糖尿病治疗中的作用。","authors":"Prabirkumar Bandyopadhyay","doi":"10.1358/dnp.2009.22.9.1434633","DOIUrl":null,"url":null,"abstract":"<p><p>Type 2 diabetes (T2D) is associated with a greatly increased risk of cardiovascular disease. An increasing need for glucose-lowering treatments is emphasized by the almost inevitable failure of monotherapy and occurrence of weight gain. Recently, novel classes of drugs derived from the incretin system have been introduced into the management of T2D. Recent advances in the field of incretin-based therapies in the management of T2D were discussed at the 45th Annual Meeting of the European Association for the Study of Diabetes, held from September 29 until October 2, 2009, in Vienna, Austria.</p>","PeriodicalId":11325,"journal":{"name":"Drug news & perspectives","volume":"22 9","pages":"559-67"},"PeriodicalIF":0.0000,"publicationDate":"2009-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":"{\"title\":\"The role of incretin-based therapies in the management of type 2 diabetes.\",\"authors\":\"Prabirkumar Bandyopadhyay\",\"doi\":\"10.1358/dnp.2009.22.9.1434633\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Type 2 diabetes (T2D) is associated with a greatly increased risk of cardiovascular disease. An increasing need for glucose-lowering treatments is emphasized by the almost inevitable failure of monotherapy and occurrence of weight gain. Recently, novel classes of drugs derived from the incretin system have been introduced into the management of T2D. Recent advances in the field of incretin-based therapies in the management of T2D were discussed at the 45th Annual Meeting of the European Association for the Study of Diabetes, held from September 29 until October 2, 2009, in Vienna, Austria.</p>\",\"PeriodicalId\":11325,\"journal\":{\"name\":\"Drug news & perspectives\",\"volume\":\"22 9\",\"pages\":\"559-67\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2009-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Drug news & perspectives\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1358/dnp.2009.22.9.1434633\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug news & perspectives","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1358/dnp.2009.22.9.1434633","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
The role of incretin-based therapies in the management of type 2 diabetes.
Type 2 diabetes (T2D) is associated with a greatly increased risk of cardiovascular disease. An increasing need for glucose-lowering treatments is emphasized by the almost inevitable failure of monotherapy and occurrence of weight gain. Recently, novel classes of drugs derived from the incretin system have been introduced into the management of T2D. Recent advances in the field of incretin-based therapies in the management of T2D were discussed at the 45th Annual Meeting of the European Association for the Study of Diabetes, held from September 29 until October 2, 2009, in Vienna, Austria.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
